Fusion Antibodies (LSE:FAB) Interest Expense : £-0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Fusion Antibodies Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Fusion Antibodies's interest expense for the six months ended in Sep. 2024 was £ -0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was £-0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Fusion Antibodies's Operating Income for the six months ended in Sep. 2024 was £ -0.79 Mil. Fusion Antibodies's Interest Expense for the six months ended in Sep. 2024 was £ -0.00 Mil. Fusion Antibodies did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Fusion Antibodies Interest Expense Historical Data

The historical data trend for Fusion Antibodies's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Antibodies Interest Expense Chart

Fusion Antibodies Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Interest Expense

Get a 7-Day Free Trial

-0.02

-0.01

Fusion Antibodies Semi-Annual Data
	Mar15	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
Interest Expense	Get a 7-Day Free Trial													-0.01	-	-	-	-

Fusion Antibodies Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.00 Mil.

Fusion Antibodies (LSE:FAB) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Fusion Antibodies's Interest Expense for the six months ended in Sep. 2024 was £-0.00 Mil. Its Operating Income for the six months ended in Sep. 2024 was £-0.79 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Sep. 2024 was £0.01 Mil.

Fusion Antibodies's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

Fusion Antibodies did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Fusion Antibodies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL

Website

https://www.fusionantibodies.com

Fusion Antibodies PLC offers various antibody engineering services for all therapeutic and diagnostic antibody development stages. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.

Fusion Antibodies Headlines

From GuruFocus

626 Financial, LLC Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor • 10-21-2022